Onesource Specialty Pharma

Onesource Specialty Pharma delivered a strong Q4 FY26 recovery with revenue of ₹428.2 croreCurrent reported value: ₹428.2 crore. No comparable prior figure is available in the source record. (up 47% QoQ) and EBITDA of ₹91.9 croreCurrent reported value: ₹91.9 crore. No comparable prior figure is available in the source record. (up >5Current reported value: 5. No comparable prior figure is available in the source record.x QoQ), driven by the start of commercial shipments of generic semaglutide drug-device combinations in India and Canada. The company reaffirmed its FY28 guidance of $400 million revenueCurrent reported value: $400 million revenue. No comparable prior figure is available in the source record. with ~40% EBITDA marginsCurrent reported value: ~40% EBITDA margins. No comparable prior figure is available in the source record., supported by capacity expansion (second line online in Q2, third by year-end) and a robust demand pipeline across regulated and emerging markets. Biologics funnel expanded 4xCurrent 4x. Reported change: +300% YoY. YoY, adding key partnerships. The related-party transaction with Ster Science was deferred due to valuation concerns from minority shareholders. Key risk: any delay in regulatory approvals or capacity ramp-up could temper the sequential growth trajectory.